Fusion Antibodies strengthens platform with patent approval in Japan

(Alliance News) - Fusion Antibodies PLC on Monday said Japan's patent office has formally granted approval to its patent application covering two families of antibodies.

Belfast-based Fusion Antibodies is a contract researcher that provides discovery, design and optimisation services for therapeutic antibodies.

The company said its application has been granted under the Japanese patent number 7853096. The patent is titled "Antibody Library and Method" and covers two families of antibodies as well as the method for the design of such antibody libraries, said Fusion Antibodies.

Fusion said the patent is anticipated to be complementary to its its offering to provide "Opti" designed antibody libraries for a range of applications.

Shares in Fusion Antibodies were up 2.2% at 13.80 pence on Monday afternoon in London.

"This patent marks an important milestone in strengthening our platform and reinforces our commitment to delivering high quality antibody solutions for both therapeutic and diagnostic innovation. With this significant step, we are accelerating our mission to transform how antibodies are designed, discovered, and optimised worldwide," said Chief Executive Adrian Kinkaid.

By Christopher Ward, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2026 Alliance News Ltd. All Rights Reserved.

Fusion Antibodies